We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Dipstick Assay Evaluated for Liver Fluke Diagnosis

By LabMedica International staff writers
Posted on 22 May 2012
A dipstick assay has been developed to diagnose fascioliasis, and its diagnostic efficacy evaluated in comparison to an immunoassay.

The dipstick uses excretory–secretory antigen from Fasciola gigantica dotted onto nitrocellulose paper using a sheet Mini-Protean II multiscreen apparatus to which human serum is applied. More...


Parasitologists at Ain Shams University (Cairo, Egypt) collected blood samples were collected from 60 individuals categorized into three groups. Group I consisted of 30 fascioliasis patients, diagnosed by detection of eggs of Fasciola in the stool and serologically by positive indirect hemagglutination test. Group II consisted of 20 patients with other parasitic diseases, and Group III consisted of 20 healthy individuals proven negative for fascioliasis and other parasitic diseases.

The enzyme linked immunosorbent assay (ELISA) was carried using a standard protocol and the absorbance was measured at 450 nm using a microplate reader. Samples were considered positive if their optical density was greater than the mean of healthy control samples plus three standard deviations. On the dipstick, a dark purple to brown band indicated a positive reaction.

The dipsticks' accuracy was 98.3%, with a sensitivity of 100%, a specificity of 96.7%, and negative predictive value of 100%. The sensitivity, specificity, and diagnostic accuracy of the ELISA were 100%, 96.7%, and 98.3%, respectively. The nitrocellulose paper and sheet Mini-Protean II multiscreen apparatus are both products of Bio-Rad (Hercules, CA, USA).

The authors concluded that the dipstick is a simple antigen and serum-conservative test requires only micrograms of parasite antigen and 20 µL of patient's sera. This test can be carried out while the patients wait, and would be more practical than what is currently done especially in rural areas and district hospitals. The test has its merit in being both qualitative, able to screen large numbers of blood samples, and quantitative assay, as the end-point titration of individual's sera can be determined. It is estimated that over 2.4 million people are infected with Fasciola species worldwide and around 91 million are at risk of infection. The study was published in the May 2012 issue of the journal Parasitology Research.

Related Links:
Ain Shams University
Bio-Rad



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.